XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Inventory | 9 Months Ended
--- | ---
Sep. 30, 2022
Inventory Disclosure [Abstract] |
Inventory | 14. INVENTORY Inventory consisted of the following:
|  | September 30, 2022 |  |  | December 31, 2021 |
|  | (in thousands) |
Raw materials |  | $ | 408 |  |  | $ | — |
Work in process |  |  | 45 |  |  |  | — |
Finished goods |  |  | 110 |  |  |  | — |
Total inventories |  | $ | 563 |  |  | $ | — |
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory on hand determined to not have a future economic benefit and acquired prior to receipt of the marketing authorization for ALBRIOZA in Canada, totaling approximately $25.7 million, was expensed as research and development expense as incurred. The Company began to capitalize the costs determined to have a probable future economic benefit associated with the production of ALBRIOZA upon receipt of Health Canada approval in June 2022. Finished goods have a shelf life of 12-15 months from the date of manufacture.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI https://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration